Please try another search
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s pipeline includes OPM-101, a potentially inhibitor of the RIPK2 target, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; OPM-102, a novel inhibitor that is in preclinical studies for the treatment of cancer; and OPM-201, a potential LRRK2 inhibitor, which is in Phase 1 clinical trial for the treatment of Parkinson’s disease. It is also developing drugs for the treatment of pancreatic and other cancers. The company was founded in 1995 and is based in Dijon, France.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review